Xavier Leroy for his new role as CEO of GIO Therapeutics Dr.

Xavier Leroy on his appointment as CEO of GIO Therapeutics! Please email us at Hello@DrGPCR.com if you want to share your work with our community. Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

s Essential Contribution to Asymmetric Mating Between Two Sibling Nematode Species: Bursaphelenchus xylophilus

Xavier Leroy, Dr. Brian Arey, and Dr. J. Silvio Gutkind. light-activated neuronal GPCR shapes behavior Methods & Updates in GPCR Research Advancements in the use of xenopus

Want to share your project in a casual way? Submit a 1-minute abstract video using this form! develop new therapies for people living with obesity, diabetes and other serious metabolic diseases X4

GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Industry News X4

Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage X4

Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis

Comparative evaluation of biased agonists Sarcosine1 , d-Alanine8 -Angiotensin (Ang) II (SD Ang II) and Sarcosine1 , Isoleucine8 -Ang II (SI Ang II) and their radioiodinated congeners binding to rat liver cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts

cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts

In this study Xin Cai et al. highlight the importance of GPCR dimers in drug discovery referring to important Wan, 2020). Xue, et al. 2015). What is the potential of targeting GPCR dimer interface in drug discovery?

The effect of CCL25 on the development of SACC in vivo was examined by a xenograft tumor model in nude

Xenograft mouse model was generated to investigate the in vivo efficacy of fentanyl.

In CRPC xenografts, antagonizing AVPR2, AVPR1A, or both significantly reduced CRPC tumor growth as well

breast cancer cells, such as inhibition of cell proliferation, colony formation, migration, invasion and xenograft

synergistically inhibited colony formation by PDAC cells and suppessed the growth of MiaPaCa-2 cells xenografted

We identified gambogic acid (GA), a natural prenylated xanthone, selectively targeting GPR108.

trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium